摘要
目的探讨草酸艾司西酞普兰与氟哌噻吨美利曲辛联合治疗脑卒中后抑郁(PSD)的效果。方法选取80例脑卒中后抑郁患者为研究对象,依据随机数字表法分为联合治疗组和常规治疗组,每组40例。常规治疗组给予草酸艾司西酞普兰治疗,联合治疗组给予草酸艾司西酞普兰联合氟哌噻吨美利曲辛治疗。分别在治疗前与治疗2、4、8周后,用美国国立卫生研究院卒中量表(NIHSS)评分、汉密尔顿抑郁量表(HAMD)24项评分,比较2组治疗有效率。结果治疗前与治疗2周后,联合治疗组和常规治疗组NIHSS量表评分相比较差异无统计学意义(P>0.05);治疗4、8周后,联合治疗组NIHSS量表评分明显低于常规治疗组(P<0.05)。治疗前联合治疗组和常规治疗组,HAMD量表评分相对比差异无统计学意义(P>0.05);治疗2、4、8周后,联合治疗组HAMD量表评分明显低于常规治疗组(P<0.05)。联合治疗组总有效率为95%,高于常规治疗组的75%(P<0.05)。结论草酸艾司西酞普兰联合氟哌噻吨美利曲辛治疗脑卒中后抑郁能够更好地改善患者抑郁症状,促进脑神经功能恢复,改善认知功能,提高生活质量,降低死亡率。
Objective To investigate the clinical effect of escitalopram oxalate combined with flupentixol and melitracen in the treatment of post-stroke depression(PSD).Methods 80 patients with post-stroke depression were selected and randomly divided into experimental group and control group.The control group was treated with escitalopram oxalate,and the experimental group was treated with escitalopram oxalate combined with flupemeticide melitrazine.NIHSS score and Hamilton Depression Scale(HAMD)24 item scores were used to compare the treatment efficiency of the two groups during four time periods which were before treatment,2 weeks after treatment,4 weeks after treatment,and 8 weeks after treatment.Results The NIHSS scale scores of the experimental group and the control group were not statistically significant before treatment and 2 weeks after treatment(P>0.05).After 4 weeks and 8 weeks of treatment,the NIHSS scale score of the experimental group was significantly lower than that of the control group(P<0.05).Before treatment,the HAMD scale score ratio of the experimental group and the control group was not statistically significant.After 2 weeks of treatment,4 weeks of treatment,and 8 weeks of treatment,the HAMD scale score of the experimental group was significantly lower than that of the control group(P<0.05).After the end of the study,the total effective rate of the experimental group was 95%,which was significantly higher than that of the control group(75%,P<0.05).Conclusion Escitalopram oxalate combined with flupentixol and melitracen in the treatment of PSD can better improve the symptoms of depression,promote the recovery of neurological function,improve the quality of life of patients,reduce the mortality rate.
作者
周保
邱虹
申银霞
ZHOU Bao;QIU Hong;SHEN Yinxia(Department of Psychiatry,The First People’s Hospital of Yinchuan,Yinchuan 750001,China)
出处
《宁夏医学杂志》
CAS
2020年第12期1093-1095,共3页
Ningxia Medical Journal
